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The practice of treating diseases with serum is 
over 100 years old. Unfortunately, variable efficacy, 
poor safety and inadequate understanding of the 
actions of specific serum components limited 
early use. Modern advances in fractionation and 
filtration technologies since the late 1940s led to the development 
of increasingly safer and pure immunoglobulin preparations. 
Currently, they are used worldwide to treat a number of immune-
mediated pathologies (Table 1). The use of immunoglobulin 
therapy in South Africa (SA) is restricted, and will likely remain so, 
given the cost involved. The incremental benefit over other forms 
of immunosuppression must be assessed carefully to justify the 
additional expense. Clinicians should have an understanding of the 
therapy, considerations for use and evidence-based quality of data 
in specific disciplines. In this review we discuss these in the context 
of current use in SA.
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Polyvalent immunoglobin, derived from pooled human plasma, can be administered via the intravenous, subcutaneous or intramuscular 
route. Therapy is standard of care in the treatment of a number of immune-mediated pathologies across disciplines. By volume, the majority 
is used in neurology (~40%). In primary immunodeficiencies, therapy reconstitutes humoral immunity at replacement doses (0.4 - 0.6 g/
kg/month), decreasing infections, and is usually lifelong. However, high doses, usually 2 g/kg total dose over five days, are required for 
immunomodulation in autoimmune and inflammatory indications. A high-quality evidence base supports use in primary antibody failure, 
Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, acute idiopathic thrombocytopenia, Kawasaki disease and 
immunobullous diseases. Low-quality evidence shows benefit in many other uncommon autoimmune and immunodeficient conditions. 
In South Africa, use of immunoglobulin therapy is restricted and, given the cost involved, will likely remain so. Therefore, the incremental 
benefit over other forms of immunosuppression, particularly corticosteroids, must be assessed carefully on a case-by-case basis. In most 
cases, therapy will be second-line or ‘rescue’ and motivation will be required. This short review aims to provide clinicians with the necessary 
understanding of the therapy, general considerations for use, and evidence base and quality thereof for well-established indications. 
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Table 1. Current major uses and grade of evidence for immunoglobulin therapy
Neurology Haematology Immunology Other
Guillain-Barré syndrome (A)*[5] Immune thrombocytopenic purpura (RCT, 
limited evidence in chronic ITP) (A) 
Primary antibody 
deficiencies (A)[33,45] 
Kawasaki disease (A)[39] 
Chronic inflammatory demyelinating 
polyradiculoneuropathy (A)[6] 
Alloimmune thrombocytopenia (feto-
maternal/neonatal)
Specific antibody deficiency 
(GPP)
Toxic epidermal 
necrolysis, Stevens-
Johnson syndrome (no 
mortality benefit)[38] 
Multifocal motor neuropathy (GPP)[7] Haemolytic disease of the newborn Secondary antibody 
deficiency (including 
myeloma, CLL (RCT), drugs 
and other causes) (GPP)[46] 
Immunobullous disease 
(A)[37] 
Myasthenia gravis (GPP)[13]
Dermatomyositis/polymyositis (GPP)[14] Autoimmune haemolytic anaemia (GPP)
Autoimmune limbic encephalitis† (GPP)[17] Post bone marrow transplantation (A)
Stiff person syndrome[16] Parvovirus B19-associated aplasia
RCT = randomised controlled trial; ITP = immune thrombocytopenia; CLL = chronic lymphocytic leukaemia.
* Grading of Recommendations Assessment, Development and Evaluation (GRADE) to rate quality of evidence in accordance with Cochrane reviews:[47] A = level A or established evidence-based 
RCT; ‘Good practice point’ (GPP) refers to current consensus opinion in the absence of level A evidence.[8] 
†Anti-N-methyl-D-aspartate; anti-voltage-gated potassium channel antibody positive.
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Fig. 1. Established and proposed mechanism of action for immunoglobulin therapy (ADCC = antibody-dependent cell-mediated cytotoxicity; FcRn = Fc 
neonatal receptor; FcγR = Fcγ receptor ; IgG = immunoglobulin G; IV Ig = intravenous immunoglobulin; Treg cells = regulatory T cells.) 
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Immunoglobulin therapy: General 
considerations
Polyvalent immunoglobulin is purified from pooled human plasma. 
This origin as a plasma product underpins the majority of general 
considerations, both advantages and disadvantages. 
Manufacture and available preparations
Fractionation of immunoglobulin from donor plasma, removing 
unwanted and/or infectious substances and  stabilising and packaging 
it for remote clinical use, is a laborious and expensive process. Only 
four registered products are available in SA (Table 2). Immunoglobulin 
preparations are available for intravenous (IV), intramuscular 
(IM) and subcutaneous (SC) administration, with concentrations 
between 2% and16%. SC administration is increasingly used for both 
immunomodulation (high dose) and replacement therapy. Product 
differences warranting clinical considerations, highlighted for SA 
products in Table 2, include varying immunoglobulin (Ig) A content, 
different stabilising sugars/amino acids, storage conditions and cost. 
Mechanisms of action
The pooling of antibodies from thousands of donors provides a 
diversity of antibody repertoires and specificities. Fig. 1 outlines 
proposed mechanisms of actions. In immunodeficiency, antibody 
replacement therapy reconstitutes fundamental humoral immunity. 
Immunomodulatory mechanisms of action are less well understood 
and are likely to differ, depending on the specific autoimmune 
pathogenesis and individual genetic background. Diseases 
responding rapidly, but with short-lived duration of efficacy, suggest 
that high serum levels of therapeutic IgG ‘neutralise’ pathogenic 
autoantibodies.[1] Other proposed mechanisms include binding or 
blocking of the antigen-binding site (anti-idiotype), enhancing IgG 
turn-over, thereby reducing circulating pathogenic IgG, as well as 
scavenging circulating complement binding sites and interfering with 
activation of the complement cascade.[1] Two excellent reviews discuss 
the immunomodulatory mechanism of action in greater depth.[2,3] 
Side-eects
The major side-effects of immunoglobulin preparations are 
summarised in Table 3. Immediate infusion-related reactions occur 
in about 1% of all IV Ig infusions, but are usually mild and can be 
treated symptomatically with simple analgesia. Moderate reactions 
can be treated with antihistamines or corticosteroids. Reactions 
usually relate to intercurrent infections or over-rapid administration 
and can be avoided with brief clinical review prior to therapy, slow 
initiation of therapy and adherence to manufacturers’ suggested 
infusion rates. However, the more serious side-effects are associated 
with high-dose IV Ig and relate to the up to fourfold increase in 
serum IgG and additional plasma proteins. One needs to monitor 
for renal impairment, which is usually reversible. Pre-hydration is 
important and it is preferable to use an IV preparation without sugars 
or the SC route of administration in patients with pre-existing renal 
disease or the elderly. Unfortunately, the choice of product options is 
currently limited in SA. 
Therapeutic use: Evidence and current 
application in SA
Immunoglobulin use is supported by high-quality evidence 
(randomised control trials (RCTs)) for certain conditions in 
neurology, haematology, immunology and dermatology (Table 1). In 
addition, Ig therapy is used off-label, and with limited evidence, for a 
wide array of other diseases with immunopathology, usually after the 
failure of first-line therapies.[4] Globally, and in SA, the largest volume 
of Ig is used by neurology (~40%), followed by haematology. In 
immunodeficiencies, immunoglobulin replacement is used in lower 
volumes but therapy tends to be lifelong. The high cost of therapy 
and lack of availability limit use worldwide, but in SA, especially in 
the public sector, this affects use – even for conditions with well-
established benefit. In the sections below we outline the evidence by 
discipline. Table 4 provides important general considerations and 
practice points prior to commencing immunoglobulin therapy.
Neurology 
Ig therapy is highly effective in a number of neuromuscular diseases, 
but the substantial cost must be considered in developing a treatment 
plan. The mechanism of action of Ig in different diseases may vary 
and therefore appropriate dosing and frequency of administration 
may differ.[1] Cochrane reviews provide good evidence that recovery 
in severe Guillain-Barré syndrome is hastened if IV Ig (0.4  g/kg 
for 5 days) or plasma exchange are started within the first two 
weeks of symptom onset.[5] There is no evidence that giving IV 
Ig after plasma exchange provides additional benefit. In chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP), IV Ig 
(one course, total dose 2  mg/kg) is superior compared with no 
treatment in inducing improvement within six weeks; for every 
three persons treated with IV Ig, one improved. However, similar 
clinical benefits were obtained at two and six weeks when IV Ig was 
compared with plasma exchange or corticosteroids (prednisone or 
IV methylprednisolone).[6] Despite limited data, one trial showed 
sustained benefit for 24 and 48 weeks using IV Ig compared with 
placebo.[6] Compared with IV methylprednisolone (0.5  g × 4 days, 
monthly), those receiving monthly courses of Ig for CIDP were 
less likely to discontinue owing to lack of efficacy or intolerance, 
but were more likely to worsen after discontinuation at 6 months.[6] 
Overall, current evidence suggests that either IV Ig or corticosteroids 
should be considered as first-line treatment for CIDP. If doses of 
the aforementioned induction treatment are required to remain 
high to maintain disease control, an additional immunosuppressant 
or immunomodulating treatment should be considered. In the 
rare case of multifocal motor neuropathy (MMN) that does not 
respond to prednisone or plasma exchange, IV Ig therapy should be 
considered based on limited evidence; however, not all patients show 
substantial responses and ongoing therapy should be re-evaluated 
regularly.[7] Based on limited evidence, IV Ig resulted in a modest, 
short-term benefit in IgM anti-myelin-associated glycoprotein 
paraproteinaemic demyelinating neuropathy.[8] There are no RCTs 
to support the use of IV Ig in paraneoplastic neuropathies,[9] diabetic 
amyotrophy or radiculoplexopathies,[10,11] vasculitic neuropathies or 
painful neuropathies associated with Sjögren’s syndrome.[12]
Based on RCTs, IV Ig (and plasma exchange) is effective in treating 
acute crises or severe worsening of myasthenia gravis (MG),[13] with 
clinically relevant effects on average after 4 - 7 days.[1] IV Ig shows 
no effect on mild to severe but stable MG.[13] There is no evidence to 
support the use of IV Ig in inclusion body myositis. Based on one RCT, 
IV Ig may be considered as additional immunosuppressive therapy in 
severe or life-threatening dermatomyositis,[14] and probably also in 
polymyositis despite the absence of RCTs.[12]  
Although a number of older RCTs using IV Ig in relapsing-
remitting multiple sclerosis showed a reduction in relapse rates, 
these effects were not consistently accompanied by a reduction in 
brain lesions on magnetic resonance imaging.[15] Currently, IV Ig may 
be indicated to reduce relapses during pregnancy and breastfeeding 
when the standard disease-modifying drugs are contraindicated.[12] One 
RCT showed IV Ig was of benefit in severe stiff person syndrome, with 
benefits lasting between six weeks and one year.[16] In the increasingly 
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recognised antibody-mediated 
limbic encephalitis, most 
frequently due to N-methyl-
D-aspartate (NMDA)-receptor 
antibodies, observations from 
a large cohort (N=577) suggest 
that steroids as well as plasma 
exchange or IV Ig may have a 
place as first-line therapy; about 
half of the patients responded 
within four weeks and did not 
require second-line therapies.[17] 
One RCT found no efficacy in 
using IV Ig as add-on therapy in 
refractory epilepsy when com-
pared with placebo.[18]      
Haematology 
Treatment with Ig has been 
found to be useful in a number 
of haematological disorders. 
Immune thrombocytopenia (ITP) 
remains a poorly understood 
disorder, where antibodies to 
platelet antigens lead to clinically 
significant platelet destruction 
that is not compensated by 
bone marrow production. The 
acute presentations are common 
in children, while chronic 
forms are dominant in adults. 
Although the initial treatment 
of ITP remains corticosteroids 
(prednisone 1 - 2 mg/kg), 
intravenous immunoglobulin 
at 0.5 - 2 g/kg has similar 
efficacy and was found to be 
cost-effective in children.[19] 
In adults, immunoglobulin 
therapy remains a second-line 
treatment, mainly owing to 
cost, but is particularly useful 
to induce a more rapid response 
in emergency situations (active 
bleeding, need for procedures 
or surgery); however, most 
responses are transient.[20] 
Overall, the effectiveness of 
this treatment is similar to 
that of corticosteroids, which 
are significantly cheaper. IV 
Ig is indicated in patients with 
thrombocytopenia secondary to 
HIV infection unresponsive to 
antiretroviral therapy, and the 
management should not differ 
from that for the idiopathic 
form.[21,22] 
Immune red cell destruc-
tion has also been a focus of 
interest for immunoglobulin 
therapy. Controlled studies have T
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suggested a reduction in parameters of red cell breakdown in 
ABO and Rh haemolytic disease of the newborn, although larger 
prospective studies are required.[23] Some retrospective data also 
support its use in fetal red cell alloimmunisation, although a meta-
analysis was unable to confirm this.[24] Immunoglobulin therapy 
was found to be effective in IgG-mediated immune haemolytic 
anaemia in only 40% of patients and is not considered as first-
line therapy, where corticosteroids are more effective.[25] However, 
immunoglobulin therapy may be more active in combination with 
steroids, where a more rapid response is observed. Anecdotal 
data suggest that the combination was also useful in hyper-
haemolysis syndrome associated with sickle cell anaemia in the 
context of intense red cell breakdown with the non-reactive direct 
antiglobulin test.[26] Pure red cell aplasia (PRCA) is characterised 
by severe anaemia with absent maturing red cell precursors in the 
marrow and reticulocytopenia. Viral infections, particularly B19 
parvovirus, are a common cause of PRCA, especially in patients 
with HIV infection or who are immunosuppressed following organ 
transplantation. Immunoglobulin therapy is particularly effective 
in this group at standard doses, with universal responses observed 
within 90 days of therapy.[27] 
Immunoglobulin therapy has been recommended in other 
situations, such as after allogeneic stem cell transplantation for the 
prevention of cytomegalovirus reactivation, although no controlled 
studies are available; however, a phase II study and retrospective review 
by Ichihara et al.[28] showed equal viral reactivation rates compared 
with the untreated group. Similarly, while anecdotal cases suggested 
effectiveness in acquired haemophilia or Von Willebrand’s disease, 
review of the available evidence does not support this approach. 
IV Ig may be reserved for patients with hypogammaglobulinaemia 
(IgG <4 g/L) after bone marrow transplantation and in adults with 
secondary antibody deficiency associated with chronic lymphocytic 
leukaemia and myeloma,[29,30] although its cost-effectiveness has been 
questioned.[31] 
Immunology
Replacement immunoglobulin therapy is life-saving and cost-
effective for patients with severe hypogammaglobulinaemia/
agammaglobulinaemia owing to primary immunodeficiencies, 
such as common variable immunodeficiency (CVID) and X-linked 
agammaglobulinaemia. However, treatment is less clear-cut for the 
spectrum of borderline hypogammaglobulinaemia, specific antibody 
deficiency or subclass deficiencies. In these cases, demonstration 
of absent or declining functional antibody responses, i.e. to test 
vaccination, in the context of documented ongoing infections, should 
warrant a 12-month trial of therapy with regular review of clinical 
response. In long-term replacement therapy, clinicians should focus 
on two fundamental components: (i) ensuring adequate dosing to 
prevent infections; and (ii) optimising and monitoring product and 
patient factors to ensure ongoing compliance, efficacy and safety. 
Most national guidelines recommend a starting dose of 400 - 
600  mg/kg/month, with higher doses for patients with structural 
lung damage, e.g. bronchiectasis.[32] Maintenance of adequate serum 
levels is critical to prevent serious bacterial infections. Pneumonia 
incidence with IV Ig therapy is five times higher at a trough IgG 
level of 5 g/L compared with 10 g/L.[33] A meta-analysis of multiple 
studies found a 27% decline in pneumonia incidence for each 
1  g/L increase in trough IgG.[33] A similar relationship is seen 
with subcutaneous immunoglobulin (SC Ig) therapy.[34] Ensuring 
adequate trough levels is cost-effective.[35] Increasingly, clinicians 
and funders are treating towards a patient’s ‘biological’ trough level 
which, similar to the normal range of serum IgG in healthy people, 
Table 3. Immunoglobulin therapy – adverse reactions*
Adverse reaction and frequency* Severity Route of administration Onset from infusion†
Common (20 - 40%) IV Ig SC Ig
Infusion site pain, swelling, erythema (up to 75% in SC Ig) Usually mild Usually immediate
Anxiety, malaise, fatigue Usually mild Usually immediate
Myalgia, arthralgia, back pain Usually mild Usually immediate
Fever, chills, flushing Usually mild Usually immediate
Tachycardia, hypo-/hypertension Usually mild Usually immediate
Headache Mild to moderate IV Ig >> SC Ig Immediate, but can be delayed
Less common (<5%)‡
Aseptic meningitis Moderate IV Ig >> SC Ig Delayed
Hyponatraemia Moderate IV Ig only Delayed
Neutropenia Mild/transient Delayed
Haemolytic anaemia Moderate to severe IV Ig >> SC Ig Delayed
Interference with vaccine effectiveness and/or immunodiagnosis N/A IV Ig = SC Ig N/A
Eczema IV Ig Delayed
Rare (<0.1%)
Anaphylactoid reaction Severe IV Ig >> SC Ig Immediate
Thrombosis Severe IV Ig Late
Blood-borne infectious disease Severe IV Ig = SC Ig N/A
Renal impairment Mild to severe IV Ig>SC Ig Delayed
IV Ig = intravenous immunoglobulin therapy; SC Ig = subcutaneous immunoglobulin; N/A = not applicable.
*Frequencies are for patients using long-term therapy. Table modified from Peter and Chapel.[32] 
†Time of onset of adverse reaction from start of infusion, immediate: within 6 hours; delayed: 6 hours to 1 week; late: week to months.
‡With the exception of anaphylactic reactions, the less common and rare side-effects tend to occur with the higher immunomodulatory doses of immunoglobulin.
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recognises that individuals may require differing trough IgG levels 
to prevent a similar number of infections. At treatment initiation, 
patients should be reviewed by a medical specialist every 2 - 3 
months, with monitoring of efficacy, serum IgG and infusion-related 
issues, but once treatment has been established six-monthly review is 
recommended.[32] 
Chronic therapy with immunoglobulin is expensive, logistically 
challenging and disruptive to patient lifestyle. To improve long-term 
compliance, physicians should involve patients and their families 
early in discussions about route of administration (IV Ig versus 
SC Ig), timing and location of therapy (clinic-based versus home-
based) as well as funding. Involvement of a specialist nurse for home 
infusion training and follow-up monitoring is important. National 
patient support groups, such as the Primary Immunodeficiency 
Network of South Africa (PINSA, http://pinsa.org.za/), offer patients 
much-needed additional support as well as a role in national 
advocacy. In SA, the majority of children and adults with primary 
immunodeficiency receive hospital-based IV Ig replacement therapy, 
often at suboptimal doses because of cost constraints. However, many 
developed countries have increasing numbers of immunodeficient 
patients performing home-based IV Ig or SC Ig therapy.[36] This 
could potentially be applied in SA, but would require a substantially 
strengthened specialist nursing and patient support infrastructure to 
ensure safety and efficacy. 
A more in-depth discussion on the issues around immunoglobulin 
replacement therapy for immunodeficiency has recently been published.[32] 
Use in other disciplines
Immunomodulation with IV Ig is also used in a number of other 
disciplines and specific conditions. In the majority of these it is used 
as ‘rescue’ therapy after the failure of first-line treatment, usually 
consisting of corticosteroids and a steroid-sparing immunosuppressant. 
In dermatology, IV Ig is used globally for blistering skin diseases. 
RCT data support the use of IV Ig for steroid-resistant pemphigus 
and pemphigoid, with a single course of a 0.4 g/kg dose for 5 days 
significantly reducing disease activity.[37] However, although widely 
used, pooled analysis shows no mortality benefit for use in patients 
with Stevens-Johnson syndrome/toxic epidermal necrolysis.[38] IV  Ig 
is a well-established first-line therapy for Kawasaki disease to prevent 
new coronary artery abnormalities, with high-quality evidence 
supporting use of a single 2  g/kg dose within 10 days of symptom 
onset.[39] Combination with corticosteroids may offer additional 
benefit.[40] There is limited evidence of benefit in other autoimmune 
vasculitides, or catastrophic antiphospholipid syndrome, and IV Ig 
is not currently recommended over less expensive therapy.[41] Large 
numbers of studies have examined the use of IV Ig and IgM-enriched 
immunoglobulin preparations for the treatment of severe bacterial 
sepsis and septic shock, and pooled data fail to show a mortality 
benefit.[42] In preterm (<37 weeks) and low-birthweight infants, IV Ig 
replacement can decrease sepsis and serious infection (by only 3 - 4%), 
with no mortality benefit.[43,44] In limited resource settings, such as 
the SA public sector, these small benefits are insufficient to justify 
routine use. 
Conclusions
Immunoglobulin therapy is an expensive and complex therapy that can 
be lifesaving. To ensure that SA patients access therapy appropriately, 
clinicians must be well informed on the available evidence base to 
motivate successfully. As many of these conditions are uncommon, 
clinicians who do not regularly prescribe immunoglobulins need 
to be aware of important product and patient factors guiding safe 
and effective use. It is hoped that this article serves as an effective 
interim measure during the ongoing development of formal SA 
immunoglobulin therapy guidelines to improve and advocate access 
and appropriate use.
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